Gurgaon Samachar

Nephropathic Cystinosis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Nephropathic Cystinosis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

August 18
13:54 2020
Nephropathic Cystinosis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Nephropathic Cystinosis – Market Insights, Epidemiology, and Market Forecast-2030”

DelveInsight has launched a new Report on “Nephropathic Cystinosis – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s Nephropathic Cystinosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Nephropathic Cystinosis , historical and forecasted epidemiology as well as the Nephropathic Cystinosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the Key Facts:

1. Cystinosis affects males and females in equal numbers. The disorder is estimated to occur in 1 in 100,000-200,000 people in the general population.

2. Cystinosis is the most common cause of renal Fanconi syndrome in children and accounts for approximately 5 percent of all childhood cases of kidney failure.

3. Nephropathic Cystinosis incidence is approximately 1:150,000 to 200,000 live births and its prevalence is approximately 1.6 per million population.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/nephropathic-cystinosis-market

 

Key benefits of the Report:

1. Nephropathic Cystinosis market report covers a descriptive overview and comprehensive insight of the Nephropathic Cystinosis epidemiology and Nephropathic Cystinosis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Nephropathic Cystinosis market report provides insights on the current and emerging therapies.

3. Nephropathic Cystinosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. Nephropathic Cystinosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nephropathic Cystinosis market.

 

“Infantile (Nephropathic Cystinosis) is the most common form of the disease, accounting for 95 % of cases.”

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/nephropathic-cystinosis-market

Nephropathic Cystinosis treatment is directed toward the specific symptoms that are apparent in each individual and is best treated by a team of specialists, who have knowledge about the disease, and who can offer supportive and symptomatic care. Care is directed toward relieving the symptoms of the disease. Cystine Depleting Therapies are now available for the Nephropathic Cystinosis treatment.

The ultimate goal of the Nephropathic Cystinosis treatment is to reduce the cystine levels in the body. The treatment approach involves cystine depleting therapies, symptomatic medications, and kidney transplant in severe cases. There are two cystine depleting therapies which are approved by the FDA for the treatment of this disease including Cystagon (Mylan Pharmaceuticals) and Procysbi (Horizon Pharma USA, Inc.). Cystagon (Mylan Pharmaceuticals) is approved for Nephropathic Cystinosis treatment in adults and children. It reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt. The body is able to remove this salt from the cells. The amount of cystine in the organs is therefore reduced, and this limits the damage to these organs.

PROCYSBI (Horizon Pharma USA, Inc.) is the other candidate which is approved for Nephropathic Cystinosis treatment in adult and pediatric patients 2 years of age and older. It participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.

Both of the therapies have received orphan drug designation from the USFDA. Apart from these therapies, certain symptomatic treatment is also advised and consequently happens to occupy a considerable share in the overall treatment landscape. Infants and young children with cystinosis receive fluid and electrolytes, such as sodium and potassium. Vitamin D and phosphate salts are also given to deal with the problems of weaker bones. Diabetes is usually managed with a low-sugar diet, insulin, or other medicines that help control sugar in the blood. In severe cases where none of the therapies is effective, kidney transplant is recommended.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/nephropathic-cystinosis-market

 

Key Companies Covered:

  • Horizon Pharma/Raptor Pharmaceuticals
  • Mylan Pharmaceuticals/Recordati
  • Leadiant Biosciences
  • Recordati S.p.A.
  • Avrobio
  • Eloxx Pharmaceuticals
  • Mylan EPD
  • And Many Others

 

Table of contents

1. Key Insights

2. Executive Summary of Nephropathic Cystinosis

3. Competitive Intelligence Analysis for Nephropathic Cystinosis

4. Nephropathic Cystinosis : Market Overview at a Glance

4.1. Nephropathic Cystinosis Total Market Share (%) Distribution in 2017

4.2. Nephropathic Cystinosis Total Market Share (%) Distribution in 2030

5. Nephropathic Cystinosis : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Nephropathic Cystinosis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Nephropathic Cystinosis Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Nephropathic Cystinosis Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Nephropathic Cystinosis Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Nephropathic Cystinosis Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Nephropathic Cystinosis Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Nephropathic Cystinosis Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Nephropathic Cystinosis Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Nephropathic Cystinosis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Nephropathic Cystinosis Treatment and Management

8.2. Nephropathic Cystinosis Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Nephropathic Cystinosis Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Nephropathic Cystinosis : Seven Major Market Analysis

13.1. Key Findings

13.2. Nephropathic Cystinosis Market Size in 7MM

13.3. Nephropathic Cystinosis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Nephropathic Cystinosis Total Market Size in the United States

15.1.2. Nephropathic Cystinosis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Nephropathic Cystinosis Total Market Size in Germany

15.3.2. Nephropathic Cystinosis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Nephropathic Cystinosis Total Market Size in France

15.4.2. Nephropathic Cystinosis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Nephropathic Cystinosis Total Market Size in Italy

15.5.2. Nephropathic Cystinosis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Nephropathic Cystinosis Total Market Size in Spain

15.6.2. Nephropathic Cystinosis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Nephropathic Cystinosis Total Market Size in the United Kingdom

15.7.2. Nephropathic Cystinosis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Nephropathic Cystinosis Total Market Size in Japan

15.8.3. Nephropathic Cystinosis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Nephropathic Cystinosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 Request for Detailed TOC: https://www.delveinsight.com/sample-request/nephropathic-cystinosis-market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/nephropathic-cystinosis-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gurgaon-samachar.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share